India allows generics of Merck & Co's Januvia for now PharmaTimes Last month, an Indian patent appeals board confirmed its decision to allow Natco's generic version of Bayer's liver and kidney cancer drug Nexavar (sorafenib) to remain on the market, having issued a compulsory licence on the treatment in 2012 and ... |
